SPECT imaging agent for FAP-alpha specific tumor diagnosis

A kit and radionuclide technology, applied in the field of broad-spectrum tumor SPECT imaging agents targeting FAP-α, can solve the problems of expensive equipment, drugs and inspections, low targeting specificity, and poor imaging effects , to achieve excellent in vivo biodistribution, high tumor uptake and tumor/organ uptake ratio, and good druggability

Active Publication Date: 2020-11-27
JIAXING PHARBERS GENESIS PHARMACEUTICAL TECHNOLOGY CO LTD
View PDF7 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Compared with the two, PET diagnosis has significant advantages in detection sensitivity, image resolution and clarity, and positioning accuracy, but its equipment, drugs and examination costs are more expensive
However, there are few types of tumor-specific SPECT imaging agents currently used clinically, the targeting specificity is not high, and the imaging effect is poor. Therefore, it is necessary to vigorously develop broad-spectrum tumor-specific SPECT imaging technology

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] The chemical synthesis of embodiment 1 HFAPi and HpFAPi

[0056] Method 1 for separation and purification of the target product by high performance liquid chromatography: Agilent 1260 HPLC system is equipped with YMC-Pack ODS-A C18 semi-preparative column (250×10mml.D.S-5μm, 12nm). Gradient elution for 25min with a flow rate of 3.2mL / min, wherein the mobile phase A is deionized water (containing 0.05% TFA), the mobile phase B is acetonitrile (containing 0.05% TFA), and the elution gradient is set to 85% A and 15% B, 85% A and 15% B at 5 min, 45% A and 55% B at 25 min.

[0057] Method 2 for separating and purifying the target product by high performance liquid chromatography: Agilent 1260 HPLC system is equipped with YMC-Pack ODS-A C18 semi-preparative column (250×10mml.D.S-5μm, 12nm). Gradient elution for 25min, flow rate 2.0mL / min, wherein the mobile phase A is deionized water (containing 0.05% TFA), the mobile phase B is acetonitrile (containing 0.05% TFA), and the e...

Embodiment 2

[0094] Example 2 Preparation of HFAPi and HpFAPi freeze-dried labeling kit

[0095] (1) Preparation of HFAPi kit

[0096] Weigh 1mg of HFAPi, dissolve it in 1mL of 75% ethanol aqueous solution, the concentration is 1μg / μL; then prepare a mixed solution containing 25μg (25μL) HFAPi, 2.0mg Tricine, 3.0mg TPPTS, 29.55mg succinic acid and 17.0mg sodium hydroxide 1mL, filtered through a 0.22μm filter membrane, added to a 10mL sterile vial, freeze-dried the mixture, sealed and capped to obtain 1 tube that can be used for 99m Tc-labeled lyophilized kit.

[0097] (2) Kit preparation of HpFAPi

[0098] Weigh 1 mg of HpFAPi, dissolve it in 1 mL of 75% ethanol aqueous solution, the concentration is 1 μg / μL; then prepare a mixed solution containing 25 μg (25 μL) HFAPi, 2.0 mg Tricine, 3.0 mg TPPTS, 29.55 mg succinic acid and 17.0 mg sodium hydroxide 1mL, filtered through a 0.22μm filter membrane, added to a 10mL sterile vial, freeze-dried the mixture, sealed and capped to obtain 1 tube...

Embodiment 399

[0099] Example 3 99m Tc-HFAPi and 99m Preparation and quality control of Tc-HpFAPi

[0100] The radiochemical purity (Radiochemical Purity, RCP) of the marker was determined using HPLC (equipped with Raytest Gabistar radioactive detector and Agilent-35900E digital-to-analog converter) and YMC-Pack ODS-A C18 analytical column (250×4.6mmml.D.S -5μm, 12nm), gradient elution for 20 minutes, flow rate 1mL / min, wherein the mobile phase A is deionized water (containing 0.05% TFA), and the mobile phase B is acetonitrile (containing 0.05% TFA). The elution gradient was set as 90% A and 10% B at the beginning, 60% A and 40% B at 17.5 min, and 90% A and 10% B at 20 min.

[0101] (1) 99m Preparation of Tc-HFAPi:

[0102] Add 1mL Na to the HFAPi freeze-dried kit (without opening the cap) 99m TCO 4 Solution (~740MBq), react in a water bath at 99°C for 15 minutes, take out the kit after the reaction and cool to room temperature to obtain the radiopharmaceutical 99m Tc-HFAPi, the struc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an SPECT imaging agent for FAP-alpha specific tumor diagnosis. The imaging agent is formed by taking a micromolecular FAP-alpha inhibitor of a modified N-4-quinolyl-glycine-(2S)-cyanoproline skeleton as a precursor compound, taking 99mTc as radionuclide and taking N-tris (hydroxymethyl) methylglycine (Tricine) and triphenylphosphine tri-m-sodium sulfonate (TPPTS) as synergistic ligands. Compared with the prior art, the imaging agent has high sensitivity, more excellent in-vivo biological distribution is shown, compared with the prior art, the complex has the advantagesof higher tumor uptake and tumor / organ uptake ratio, more stable coordination property, and excellent in-vivo and in-vitro stability. Due to the obvious coordination structure characteristics of theimaging agent, a one-step marking kit technology can be used, and the imaging agent has better druggability and is suitable for industrial production and clinical popularization.

Description

technical field [0001] The invention relates to a radionuclide-labeled diagnostic drug complex, including a precursor compound for preparing the complex and a pharmaceutical composition or a pharmaceutical kit, in particular to a broad-spectrum tumor SPECT targeting FAP-α imaging agent. Background technique [0002] 90% of the deaths in patients with malignant tumors are caused by metastasis, but preventive or therapeutic strategies for tumor metastasis are still lacking. [0003] Tumor is a complex composed of tumor cells and their surrounding stromal cells and non-cellular components. The occurrence and development of tumors is a dynamic process of mutual promotion and co-evolution between tumor cells and their microenvironment. The tumor microenvironment includes cells and extracellular matrix, and the formed components are mainly cellular components, including immune cells, endothelial cells, fibroblasts, etc. Among them, cancer associated fibroblasts (CAFs) are the mos...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K51/04A61K103/10
CPCA61K51/0482
Inventor 贾兵王凡杨广杰高瀚男李小达史继云马庆杰高识
Owner JIAXING PHARBERS GENESIS PHARMACEUTICAL TECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products